Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585052 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
A Phase 2 study, sponsored by University of Iowa.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00585052 is a Phase 2 study that was terminated before completion, run by University of Iowa. The registered enrollment target is 11 participants.
The verdict
NCT00585052, a Phase 2 study, was terminated before completion, sponsored by University of Iowa.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if the treatment combination of paclitaxel and lovastatin is more effective than the currently available chemotherapy for refractory or relapsed ovarian cancer. This research is being done to improve on currently available chemotherapy for ovarian cancer.
Interventions
- DRUG Paclitaxel
- DRUG Lovastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2003-08 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00585052
The ClinicalTrials.gov registry entry for NCT00585052 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT00585052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00585052 about?
NCT00585052 is a clinical study titled "A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer". The purpose of this study is to find out if the treatment combination of paclitaxel and lovastatin is more effective than the currently available chemotherapy for refractory or relapsed ovarian cancer. This research is being done to improve on currently available chemotherapy for ovarian cancer.
What is the current status of trial NCT00585052?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2003-08. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00585052?
The interventions under investigation include: Paclitaxel (DRUG), Lovastatin (DRUG).
Who is sponsoring clinical trial NCT00585052?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.